What is the equity of bioXXmed this year?
bioXXmed has equity of 21.42 M EUR this year.
bioXXmed Equity 2024
bioXXmed Equity
21.42 M EUR
bioXXmed Dividend yield
Ticker
T5O.DE
ISIN
DE000A0KFRJ1
WKN
A0KFRJ
In 2024, bioXXmed's equity was 21.42 M EUR, a 19.88% increase from the 17.87 M EUR equity in the previous year.
bioXXmed Aktienanalyse
What does bioXXmed do?
CytoTools AG is a German biotechnology company based in Darmstadt. It was founded in 2000 and has been listed on the Frankfurt Stock Exchange since 2006. The company focuses on the development of innovative therapies for diseases that have been difficult or impossible to treat so far. CytoTools relies on the use of active substances developed based on endogenous (body's own) molecules. A particular focus is on the research and development of active substances for the treatment of diseases based on inflammatory processes. CytoTools works closely with international research and development partners in this area. CytoTools' business model is based on the development and marketing of products based on innovative technologies and active substances. As a biotechnology company, it specializes in the development of patent-protected products and pursues a scalable business model. The company is divided into various divisions. In the "Pharmaceuticals" division, CytoTools develops innovative active substances and drugs for the treatment of diseases such as inflammatory diseases, cancer, or diabetes. An example of this is the active substance DermaPro, which can be used to treat chronic wounds. In the "Medical Devices" division, CytoTools develops medical devices for the diagnosis and therapy of diseases. An example of this is the CytoSorb system, which is used for extracorporeal blood detoxification and thus supports the treatment of severe infectious and inflammatory diseases. The third division of CytoTools is "Diagnostics". Here, the company develops innovative diagnostic tools for early detection of diseases. An example of this is the biomarker-based rapid test DermaPro Inflammation Score, which allows for a quick and reliable assessment of the inflammatory state of wounds. CytoTools has a strong network of partners and cooperation partners. The most important partners include institutions such as Kiel University, Flensburg University, or the Institute of Molecular Biotechnology in Jena. In addition, CytoTools works closely with international partners from the pharmaceutical industry. Overall, CytoTools is an innovative and rapidly growing biotechnology company specializing in the development of patent-protected products and technologies for the treatment of severe and previously incurable diseases. With its strong network of research and development partners and a wide range of products, the company is well-positioned to continue growing and develop new therapy concepts in the future. bioXXmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing bioXXmed's Equity
bioXXmed's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding bioXXmed's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating bioXXmed's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
bioXXmed's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in bioXXmed’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about bioXXmed Stock
What was the equity of bioXXmed compared to the previous year?
The equity of bioXXmed has increased/decreased by 19.88% increased compared to the previous year.
What impact does a high equity have on investors of bioXXmed?
A high equity is advantageous for investors of bioXXmed as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of bioXXmed?
A low equity can be a risk for investors of bioXXmed, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of bioXXmed affect the company?
An increase in equity of bioXXmed can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of bioXXmed affect the company?
A reduction in equity of bioXXmed can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of bioXXmed?
Some factors that can affect the equity of bioXXmed include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of bioXXmed so important for investors?
The equity of bioXXmed is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can bioXXmed take to change the equity?
To change equity, bioXXmed can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does bioXXmed pay?
Over the past 12 months, bioXXmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, bioXXmed is expected to pay a dividend of 0 EUR.
What is the dividend yield of bioXXmed?
The current dividend yield of bioXXmed is .
When does bioXXmed pay dividends?
bioXXmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of bioXXmed?
bioXXmed paid dividends every year for the past 0 years.
What is the dividend of bioXXmed?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is bioXXmed located?
bioXXmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von bioXXmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of bioXXmed from 5/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/19/2024.
When did bioXXmed pay the last dividend?
The last dividend was paid out on 5/19/2024.
What was the dividend of bioXXmed in the year 2023?
In the year 2023, bioXXmed distributed 0 EUR as dividends.
In which currency does bioXXmed pay out the dividend?
The dividends of bioXXmed are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von bioXXmed
Our stock analysis for bioXXmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of bioXXmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
